Drug Patents owned by Amgen Inc

1. Drug name - CORLANOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(4 years from now)

CN100402502C AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600B AMGEN INC Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827602A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600485I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600486I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN269993B AMGEN INC Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride
Feb, 2026

(3 years from now)

IN237447B AMGEN INC A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition
Feb, 2026

(3 years from now)

EP1695965B1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562B1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965B9 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562A1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965A1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361650

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Aug, 2026

(3 years from now)

US7361649

(Pediatric)

AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Aug, 2026

(3 years from now)

US7879842

(Pediatric)

AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Aug, 2026

(3 years from now)

US7867996

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Jun, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 7.5MG BASE TABLET;ORAL Prescription

2. Drug name - CORLANOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(4 years from now)

CN100402502C AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600B AMGEN INC Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827602A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600485I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600486I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN269993B AMGEN INC Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride
Feb, 2026

(3 years from now)

IN237447B AMGEN INC A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition
Feb, 2026

(3 years from now)

EP1695965B1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562B1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965B9 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562A1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965A1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

Drugs and Companies using IVABRADINE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/5ML (1MG/ML) SOLUTION;ORAL Prescription

3. Drug name - LUMAKRAS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10519146 AMGEN INC KRAS G12C inhibitors and methods of using the same
May, 2038

(15 years from now)

US11236091 AMGEN INC Solid state forms
May, 2040

(17 years from now)

EP3630761A1 AMGEN INC Kras G12C Inhibitors And Methods Of Using The Same
May, 2038

(15 years from now)

EP3630761B1 AMGEN INC Kras G12C Inhibitors And Methods Of Using The Same
May, 2038

(15 years from now)

Drugs and Companies using SOTORASIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
120MG TABLET;ORAL Prescription

4. Drug name - OTEZLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7893101 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Dec, 2023

(1 year, 2 months from now)

US7427638 AMGEN INC (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
Feb, 2028

(5 years from now)

CN1965823A AMGEN INC (+)-2-(1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl)-4-Acetylamino Isoindoline-1,3-Dione, Synthesis Method And Composition Thereof
Mar, 2023

(5 months from now)

CN1652772A AMGEN INC (+) -2-[1 - (3-Ethoxy - -4 - Methoxyphenyl)--2 - Ethyl]--4--4-Acetylamino--1, 3-Diketone Using The Method And Composition Thereof
Mar, 2023

(5 months from now)

CN100427085C AMGEN INC (+) -2-[1 - (3-Ethoxy - -4 - Methoxyphenyl)--2 - Ethyl]--4--4-Acetylamino--1, 3-Pharmaceutical Use Of Diketone
Mar, 2023

(5 months from now)

CN1965823B AMGEN INC (+) -2-[3 - (1-Ethoxy - -4 - Methoxyphenyl) -2 - Methylsulfonyl-Ethyl] -4 - Stereomeric - -1, 3-Diketone, Its Synthetic Method And Its Composition
Mar, 2023

(5 months from now)

EP2074995A1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Feb, 2018

(4 years ago)

EP2074995B1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Feb, 2018

(4 years ago)

EP2223687A1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Aug, 2018

(4 years ago)

EP2223687B1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Aug, 2018

(4 years ago)

EP2223688B1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Oct, 2021

(11 months ago)

EP2223688A1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Oct, 2021

(11 months ago)

EP2311453B1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2420490B1 AMGEN INC Method For The Preparation Of (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
Mar, 2023

(5 months from now)

EP2295055A3 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2295055B1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2311453A1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2295055A2 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP1485087A1 AMGEN INC (+)-2- [1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione For Use In Treating Psoriasis By Oral Administration
Mar, 2023

(5 months from now)

EP2420490A1 AMGEN INC Method For The Preparation Of (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
Mar, 2023

(5 months from now)

EP1485087B1 AMGEN INC (+)-2- [1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione For Use In Treating Psoriasis By Oral Administration
Mar, 2023

(5 months from now)

EP2962690B1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2962690A1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9724330 AMGEN INC Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione Mar, 2023

(5 months from now)

US8802717 AMGEN INC Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione Mar, 2023

(5 months from now)

US7208516 AMGEN INC Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione Mar, 2023

(5 months from now)

US7659302 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione Mar, 2023

(5 months from now)

US8455536 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione Mar, 2023

(5 months from now)

US9018243 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof Mar, 2023

(5 months from now)

US6962940 AMGEN INC (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof Mar, 2023

(5 months from now)

US9872854 AMGEN INC Methods for the treatment of psoriatic arthritis using apremilast May, 2034

(11 years from now)

US10092541 AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast May, 2034

(11 years from now)

Drugs and Companies using APREMILAST ingredient

Treatment: Use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with active psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriatic arthritis; Use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for inhibiting pde4; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Treatment of psoriatic arthritis using a dosage titration schedule; treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent; Treatment of psoriasis using a dosage titration schedule; treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.